SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yusuke Narita, Yukiko Matsushima, Takeru Shiroiwa, Koji Chiba, Yoichi Nakanishi, Tatsuo Kurokawa, Hisashi Urushihara, Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer, Lung Cancer, 2015,

    CrossRef

  2. 2
    Katharina Schremser, Wolf H. Rogowski, Sigrid Adler-Reichel, Amanda L. H. Tufman, Rudolf M. Huber, Björn Stollenwerk, Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany, PharmacoEconomics, 2015,

    CrossRef

  3. 3
    Donna M. Graham, Natasha B. Leighl, Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine, Frontiers in Oncology, 2014, 4,

    CrossRef

  4. 4
    Unchalee Permsuwan, Narawadee Niamhun, Narumon Tanatip, Sumitra Thongprasert, Epidermal Growth Factor Receptor Mutation Testing in Thailand: A Cost-Utility Analysis, Value in Health Regional Issues, 2014, 3, 39

    CrossRef

  5. 5
    Susanne B Haga, Nancy M Allen LaPointe, Alex Cho, Shelby D Reed, Rachel Mills, Jivan Moaddeb, Geoffrey S Ginsburg, Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting, Pharmacogenomics, 2014, 15, 13, 1677

    CrossRef

  6. 6
    Charles Lim, Melissa Sergi, Natasha B Leighl, Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions, Lung Cancer Management, 2014, 3, 6, 477

    CrossRef

  7. 7
    Jim Lee, Erik Tollefson, Matthew Daly, Edward Kielb, A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies, Expert Review of Pharmacoeconomics & Outcomes Research, 2013, 13, 3, 361

    CrossRef

  8. 8
    C. Chouaid, I. Borget, A. Vergnenègre, Aspects médico-économiques de la prise en charge des cancers du poumon non à petites cellules : maintenir la qualité de la prise en charge dans un cadre économique contraint, Revue des Maladies Respiratoires Actualités, 2013, 5, 5, 557

    CrossRef

  9. 9
    Jason C. Barnett, Angeles Alvarez Secord, David E. Cohn, Charles A. Leath, Evan R. Myers, Laura J. Havrilesky, Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer, Cancer, 2013, 119, 20
  10. 10
    Chong-Kin Liam, Mohamed Ibrahim A. Wahid, Pathmanathan Rajadurai, Yoke-Kqueen Cheah, Tiffany Shi-Yeen Ng, Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients, Journal of Thoracic Oncology, 2013, 8, 6, 766

    CrossRef

  11. 11
    Jun Zhu, Te Li, Xiaohui Wang, Ming Ye, Jian Cai, Yuejuan Xu, Bin Wu, Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis, BMC Cancer, 2013, 13, 1, 39

    CrossRef

  12. 12
    James A Lee, Lukas Bubendorf, Rolf Stahel, Solange Peters, Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives, Expert Review of Anticancer Therapy, 2013, 13, 5, 625

    CrossRef

  13. 13
    Alain Vergnenegre, Isabelle Borget, Christos Chouaid, Treatment of lung cancer: will financial issues become a criterion of choice?, Expert Review of Pharmacoeconomics & Outcomes Research, 2013, 13, 3, 273

    CrossRef

  14. 14
    Sumitra Thongprasert, Ask the Experts:EGFRmutation and non-small-cell lung cancer: EGFR test, cost and quality of life, Lung Cancer Management, 2012, 1, 3, 169

    CrossRef

  15. 15
    Kai Yeung, Josh J Carlson, Clinical and economic review of erlotinib in non-small-cell lung cancer, Expert Review of Pharmacoeconomics & Outcomes Research, 2012, 12, 4, 411

    CrossRef

  16. 16
    S Verduyn, Bonne Biesma, Franz MNH Schramel, Feike W van der Scheer, Merel K Langenfeld, Maria A de Peuter, Anne-Marie C Dingemans, Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands, Health and Quality of Life Outcomes, 2012, 10, 1, 108

    CrossRef

  17. 17
    C. Chouaid, P. Crequit, G. Rousseau-Bussac, Impact médico-économique du cancer du poumon, Revue des Maladies Respiratoires Actualités, 2012, 4, 6, 662

    CrossRef

  18. 18
    Linda Mileshkin, Bhaumik Shah, Michael Michael, Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?, Chemotherapy Research and Practice, 2012, 2012, 1

    CrossRef

  19. 19
    A J Atherly, D R Camidge, The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers, British Journal of Cancer, 2012, 106, 6, 1100

    CrossRef

  20. 20
    Frédérique Nowak, Jean-Charles Soria, Fabien Calvo, Tumour molecular profiling for deciding therapy—the French initiative, Nature Reviews Clinical Oncology, 2012, 9, 8, 479

    CrossRef

  21. 21
    Adnan Hasanovic, Daphne Ang, Andre L. Moreira, Maureen F. Zakowski, Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma, Lung Cancer, 2012, 77, 2, 299

    CrossRef